Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule.
PLANTATION, Fla. and GAITHERSBURG, Md., Jan. 28, 2025 /PRNewswire/ -- miRecule, a biotechnology company pioneering RNA therapies, and GBI Biomanufacturing, a leading ...
miRecule, a biotechnology company focusing on RNA therapies, and GBI Biomanufacturing, a CDMO, partnered to advance the development and clinical supply of miRecule’s Antibody-RNA Conjugate (ARC ...
(MENAFN- PR Newswire) Under the agreement, GBI will leverage its expertise and state-of-the-art facilities to support miRecule in the development and clinical production of its ARC therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results